Sleep Apnea News and Research

RSS

FDA approves minimally invasive procedure for treating benign and malignant tumors

A minimally invasive surgical approach developed by head and neck surgeons at the University of Pennsylvania School of Medicine has been cleared by the U.S. Food and Drug Administration (FDA). The

5 Jan 2010

Erectile dysfunction linked to RLS in older men

A study in the Jan. 1 issue of the journal Sleep shows that erectile dysfunction was more common in older men with restless leg syndrome (RLS) than in those without RLS, and the magnitude of this association increased with a higher frequency of RLS symptoms.

3 Jan 2010

AGD Web portal offers handy tips on oral health care

This is the time of year when we all make the same old New Year's resolutions. Exercise more. Eat better. Lose weight. What about committing to better dental health?

31 Dec 2009

FDA extends action date for its review of Cephalon's sNDA for NUVIGIL Tablets

Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].

22 Dec 2009

InHealth to further understand socioeconomic impact of medical devices and diagnostics

As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.

19 Dec 2009

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

Ethicon and Acclarent announce definitive merger agreement

Ethicon, Inc., a Johnson & Johnson company and a worldwide leader in surgical care, and Acclarent, Inc., a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT), today announced a definitive merger agreement whereby Ethicon will acquire Acclarent in an all-cash transaction for approximately $785 million net of estimated cash on hand at time of closing.

17 Dec 2009

Being obese increases the risk for developing OSA in adolescents, study shows

A study in the Dec. 15 issue of the Journal of Clinical Sleep Medicine shows that being overweight or obese increases the risk for developing obstructive sleep apnea (OSA) in adolescents but not in younger children.

15 Dec 2009

New technique to determine pediatric OSA

Researchers at the University of Chicago have discovered a technique that is able to determine whether a child has obstructive sleep apnea (OSA) or habitual snoring by screening their urine.

7 Dec 2009

Guidepoint Global launches Sleep Apnea Tracker

Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects trends and market share in the worldwide Sleep Apnea market.

4 Dec 2009

Lung disease linked to the use of contaminated well water in a CPAP machine

Many people rely on continuous positive airway pressure (CPAP) machines as a safe and effective treatment for sleep apnea. But a new case report describes a rare complication—a lingering inflammatory disease of the lungs, apparently related to the use of contaminated well water in a CPAP machine. The report appears in the December Southern Medical Journal, official journal of the Southern Medical Association.

3 Dec 2009

Repeated use of ecstasy drug increases the risk of developing sleep apnea

Repeated use of the drug popularly known as "ecstasy" significantly raises the risk of developing sleep apnea in otherwise healthy young adults with no other known risk factors for the sleep disturbance, a new study by Johns Hopkins scientists suggests.

2 Dec 2009

ImThera Medical implants its aura6000 neurostimulation device in two OSA patients

ImThera Medical, Inc. today announced that two patients have been surgically implanted with ImThera’s aura6000™ neurostimulation device for treating tongue-based Obstructive Sleep Apnea (OSA). Patients are being enrolled in ImThera’s pilot clinical investigation in Belgium with the first results expected to be published in the first half of 2010.

2 Dec 2009

J&JPRD submits an NDA for tapentadol ER tablets

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older.

2 Dec 2009

Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients

Sleep apnea is common in individuals who receive a kidney transplant and is associated with increased risk of high blood pressure, heart disease or stroke, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

20 Nov 2009

CleveMed to distribute its products in Europe and Canada following receipt of the CE Mark and CMDCAS

CleveMed recently received ISO 13485 certification issued by BSI Management Systems America Inc., one of the foremost auditing bodies in the world. CleveMed has also received the CE Mark and CMDCAS allowing its products to be distributed to the large European and the Canadian markets which will strengthen its worldwide market presence.

19 Nov 2009

CMS policy changes to drive the sleep management devices market

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, policy changes made by the Center for Medicare and Medicaid Services (CMS) will cause a surge in obstructive sleep apnea (OSA) diagnostic testing and treatment. MRG's new US Market Opportunities for Respiratory and Sleep Management Devices 2010 report finds that increasing reimbursement opportunities for OSA diagnosis and treatment will drive the OSA market to $1.5 billion by 2014.

17 Nov 2009

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000, or $0.07 per share for the corresponding prior year period.

16 Nov 2009

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Fewer than one-third of patients with heart failure are taking the three types of medications that are most effective in prolonging life and improving quality of life. The November issue of Mayo Clinic Health Letter provides an overview of treatments recommended by national guidelines.

16 Nov 2009

Self-care tips for hemorrhoids from Mayo Clinic

By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem.

16 Nov 2009

Sleep Apnea News and Research

FDA approves minimally invasive procedure for treating benign and malignant tumors

Erectile dysfunction linked to RLS in older men

AGD Web portal offers handy tips on oral health care

FDA extends action date for its review of Cephalon's sNDA for NUVIGIL Tablets

InHealth to further understand socioeconomic impact of medical devices and diagnostics

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Ethicon and Acclarent announce definitive merger agreement

Being obese increases the risk for developing OSA in adolescents, study shows

New technique to determine pediatric OSA

Guidepoint Global launches Sleep Apnea Tracker

Lung disease linked to the use of contaminated well water in a CPAP machine

Repeated use of ecstasy drug increases the risk of developing sleep apnea

ImThera Medical implants its aura6000 neurostimulation device in two OSA patients

J&JPRD submits an NDA for tapentadol ER tablets

Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients

CleveMed to distribute its products in Europe and Canada following receipt of the CE Mark and CMDCAS

CMS policy changes to drive the sleep management devices market

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Self-care tips for hemorrhoids from Mayo Clinic

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News